A safer way to freeze and store cell-based therapies
Establishment of a First-in-Class Biocompatible and Efficient Cryopreservation Technology Platform for the Next Generation of Cell-Based Therapeutics in Regenerative Medicine and Drug Discovery
This project develops a non-toxic freezing solution to help preserve cell and tissue therapies so patients needing regenerative treatments can get higher-quality materials.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cryocrate, LLC NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-11190815 on NIH RePORTER |
What this research studies
If you might receive a cell or tissue therapy in the future, this project aims to make those materials safer and more reliable to store. The team has created OdinSol®, a biocompatible cryopreservation medium that removes toxic penetrating chemicals and can keep cells stable in standard -80°C freezers. The work includes GMP-scale production, laboratory (in vitro) tests and animal (in vivo) tests of safety and function, and partnerships with manufacturing and regulatory experts to prepare for FDA clearance as a storage device for transplantable tissues. Success would make it easier for clinics and banks to store and ship cell therapies for patients.
Who could benefit from this research
Good fit: People who are candidates for cell- or tissue-based regenerative treatments (for example patients considered for iPSC-derived cell transplants) would be the primary group to benefit from this work.
Not a fit: Patients whose care does not involve cell- or tissue-based therapies are unlikely to receive direct benefits from this project.
Why it matters
Potential benefit: If successful, this technology could improve the survival and function of stored cell therapies, making regenerative treatments safer and more available.
How similar studies have performed: This is a novel, first-in-class approach: prior standard methods use toxic penetrating cryoprotectants, while early preclinical work on OdinSol® suggests improved cell survival but clinical benefit is not yet proven.
Where this research is happening
Columbia, United States
- Cryocrate, LLC — Columbia, United States (Active)
Researchers
- Principal investigator: Han, Xu — Cryocrate, LLC
- Study coordinator: Han, Xu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.